Squamous Cell Carcinoma News and Research RSS Feed - Squamous Cell Carcinoma News and Research

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.
UC San Diego scientists reveal surprising role for Hippo pathway in subduing tumor immunogenicity

UC San Diego scientists reveal surprising role for Hippo pathway in subduing tumor immunogenicity

Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings, published in Cell on December 1, could have a clinical role in improving efficiency of immunotherapy drugs. [More]
New ULB study shows how cancer cell of origin controls malignant transition

New ULB study shows how cancer cell of origin controls malignant transition

Researchers at the Université libre de Bruxelles, ULB define for the first time how the cancer cell of origin controls invasive and metastatic properties of tumor cells. [More]
Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016. [More]
Study shows new drug combination effective in treating precancerous skin lesions

Study shows new drug combination effective in treating precancerous skin lesions

A combination of two topical drugs that have been in use for years triggers a robust immune response against precancerous skin lesions, according to a new study. The research, from Washington University School of Medicine in St. Louis and Harvard Medical School, shows that the therapy activates the immune system's T cells, which then attack the abnormal skin cells. [More]
T cell channel could be potential new target for treating head and neck cancers

T cell channel could be potential new target for treating head and neck cancers

Researchers at the University of Cincinnati have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers. [More]
Sanford opens new immunotherapy study on colorectal cancer

Sanford opens new immunotherapy study on colorectal cancer

Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer. [More]
Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen. [More]
Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen. [More]
New study highlights need for routine skin cancer screening for all transplant patients

New study highlights need for routine skin cancer screening for all transplant patients

A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer. [More]
IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

IMRT linked to reduced xerostomia and feeding tube dependency in oropharyngeal cancer patients

Radiation therapy is the main treatment modality in the management of head and neck cancer. [More]
Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. [More]
Study finds nonwhite transplant recipients at risk for skin cancer

Study finds nonwhite transplant recipients at risk for skin cancer

A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer. [More]

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. [More]
Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a new study by researchers at the Stanford University School of Medicine. [More]
Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced the launch of two human recombinant antigens, expanding the company's portfolio of Critical Raw Materials for the in vitro diagnostics market. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
Advertisement
Advertisement